A5103137823- Cancer Treatment and Pharmacology
- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Chemotherapy-related skin toxicity
- Breast Cancer Treatment Studies
- Chronic Lymphocytic Leukemia Research
- Cancer-related Molecular Pathways
- Drug-Induced Adverse Reactions
- Nausea and vomiting management
- PARP inhibition in cancer therapy
- Anesthesia and Pain Management
- Cancer Cells and Metastasis
- Cancer Genomics and Diagnostics
- Cancer Diagnosis and Treatment
- Cancer survivorship and care
- DNA Repair Mechanisms
- Monoclonal and Polyclonal Antibodies Research
- PI3K/AKT/mTOR signaling in cancer
- Sympathectomy and Hyperhidrosis Treatments
- Colorectal Cancer Treatments and Studies
- Microfluidic and Bio-sensing Technologies
- Single-cell and spatial transcriptomics
- Neutropenia and Cancer Infections
- Chemotherapy-induced cardiotoxicity and mitigation
- Amoebic Infections and Treatments
The Ohio State University
2013-2023
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
2013-2023
The Ohio State University Wexner Medical Center
2012-2020
Kettering University
2020
Memorial Sloan Kettering Cancer Center
2020
Yale University
2016
The University of Texas MD Anderson Cancer Center
2016
Daiichi Sankyo (Germany)
2016
Daiichi-Sankyo (South Korea)
2016
Bristol-Myers Squibb (Switzerland)
2016
Circulating tumor cells (CTCs) are commonly isolated from the blood by targeting epithelial cell adhesion molecule (EpCAM) through positive selection. However, EpCAM can be downregulated during metastatic progression, or it initially not present. We designed present prospective trial to characterize CTCs as well other circulating populations in samples women with breast cancer without EpCAM-dependent enrichment and/or isolation technology.A total of 32 patients were enrolled, and processed...
Purpose Ado-trastuzumab emtansine (T-DM1) is currently approved for treatment in patients with human epidermal growth factor receptor 2 (HER2)-positive, metastatic breast cancer (MBC) who previously received trastuzumab and a taxane. However, there are no data on the activity of T-DM1 prior pertuzumab, which now included as standard first-line therapy. The goal this study was to assess efficacy routine clinical practice contemporary patient population that both pertuzumab. Patients Methods...
Paclitaxel-based chemotherapy continues to be an integral component in the treatment of many solid tumors. Prolonged use paclitaxel may result repeated doses premedications and potential unwanted side effects. Infusion hypersensitivity reactions occurring beyond second dose are infrequent not well characterized. We hypothesized that patients whose were discontinued after two unlikely experience infusion with subsequent doses.Patients receiving paclitaxel-based who did reaction their first or...
Complete bone marrow infiltration with profound pancytopenia is very uncommon in breast cancer. Bone metastasis can frequently occur following development of metastatic However, failure as the herald this disease not typically seen. Very limited data exists to safest and most efficacious manner treat patients due solid tumor involvement. In case, patient's thrombocytopenia was particularly worrisome, requiring daily platelet transfusions. There also concern that cytotoxic chemotherapy would...
Poly(ADP-ribose) polymerase inhibitors (PARPis) are U.S. Food and Drug Administration (FDA) approved for treatment of BRCA-mutated metastatic breast cancer. Furthermore, the BROCADE studies demonstrated benefit adding an oral PARPi, veliparib, to carboplatin paclitaxel in patients with cancer harboring BRCA mutation. Given multiple possible dosing schedules potential this regimen defective DNA repair beyond BRCA, we sought find recommended phase II dose (RP2D) schedule veliparib combination...
Fosaprepitant (Emend®) is an antiemetic frequently used for the prevention of chemotherapy-induced nausea and vomiting. We previously documented overall 28.7% incidence infusion-site reactions in patients receiving fosaprepitant via peripheral venous access. These data resulted a practice change within our institution; administered more dilute concentrations over 30 min to prevent these adverse events. This retrospective study explored impact this on reactions.Medical records with cancer...
Background Pertuzumab-based neoadjuvant chemotherapy (NAC) has demonstrated successful pathologic complete response (pCR) rates when administered to patients with human epidermal growth factor receptor 2 (HER2)-positive, locally advanced breast cancer and become standard of care. This study aimed identify pCR in receiving a variety pertuzumab-based NAC regimens. The effect the addition an anthracycline impact taxane sequencing on was also assessed. Methods A retrospective, single-center...
The immunomodulatory impact of corticosteroids and concurrent chemotherapy is poorly understood within triple-negative breast cancer (TNBC). On a biochemical level, steroids have been linked to the signaling chemotherapy-resistant pathways. However, on clinical play an essential role in tolerance through prevention chemotherapy-induced nausea vomiting (CINV) hypersensitivity reactions. Given these conflicting roles, we wanted evaluate this interplay more rigorously context early-stage TNBC....
Owing to wide availability, low cost and avoidance of ethical concerns, umbilical cord blood (UCB) provides an attractive source stem cells for investigational therapeutic uses. In this study, we sought characterize the gene expression changes as from UCB differentiate toward alveolar type II pneumocytes (ATII). Control experimental were cultured in maintenance medium (mesenchymal cell growth medium) or differentiation (small airway (SAGM)), respectively, 8 days. Total RNA was isolated...
The management of endocrine therapy resistance is one the most challenging facets advanced breast cancer treatment. Palbociclib an inhibitor cyclin-dependent kinases 4 and 6 approved for treatment hormone receptor-positive, human epidermal growth factor receptor 2-negative or metastatic in combination with fulvestrant postmenopausal women disease progression following therapy. However, responsiveness tumors to palbociclib after multiple lines not clearly established. purpose this study was...
Abstract BACKGROUND Genomic profiling and precision medicine have revolutionized cancer care but are not accessible to all due high costs, insurance issues, limited access testing facilities or qualified personnel. We established a program providing free clinical genomic worldwide (Make-An-IMPACT) report findings from the pediatric CNS tumor cohort. METHODS Following referral from: (1) physician, (2) disease-specific advocacy group, (3) submission of contact information through website,...